Interleukin 23 and Interleukin 17 Evaluation Before and After Methotrexate Treatment of Basal Cell Carcinoma.

Background: Interleukin 23 (IL 23) and Interleukin 17 (IL 17) are two vital cytokines encountered in cutaneous and non-cutaneous immune-mediated inflammatory conditions and also share in cancer development. Basal cell carcinoma (BCC) is a well-known skin tumor with a high incidence and locally invasive effect but rare metastatic potential and a low mortality rate. The aim of study was to investigate the association of IL 23 and IL 17 in BCC by immunohistochemical evaluation of both Methods: Based on a study conducted by us, twenty patients with BCC previously treated with intralesional methotrexate were involved in this study. Both interleukins were evaluated in tumor cells and inflammatory cells pre and post treatment, and expression was compared with treatment response. Resuts: Overexpression of IL 23 and IL 17 was observed in BCC, moreover, both were decreased post treatment with a significant difference (p <0.001 for both). The relationship between expression and treatment response showed more decreased expression with better response, significantly within tumor cells expressing IL 17 (p <0.005). Conclusions: IL 23 and IL 17 could be considered as main cytokines sharing in BCC progression and anti-IL 23 and anti-IL 17 therapies might be beneficial. [ABSTRACT FROM AUTHOR]

Copyright of Zagazig University Medical Journal is the property of Association of Arab Universities and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)